- Home
- PETS vs RGLS Comparison
PETS vs RGLS Comparison
Compare PETS & RGLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- RGLS
- Stock Information
- Founded
- PETS 1996
- RGLS 2007
- Country
- PETS United States
- RGLS United States
- Employees
- PETS N/A
- RGLS N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- RGLS Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- RGLS Health Care
- Exchange
- PETS Nasdaq
- RGLS Nasdaq
- Market Cap
- PETS 118.8M
- RGLS 102.1M
- IPO Year
- PETS N/A
- RGLS 2012
- Fundamental
- Price
- PETS $5.58
- RGLS $1.62
- Analyst Decision
- PETS Sell
- RGLS Strong Buy
- Analyst Count
- PETS 2
- RGLS 6
- Target Price
- PETS $3.50
- RGLS $10.33
- AVG Volume (30 Days)
- PETS 296.2K
- RGLS 261.9K
- Earning Date
- PETS 02-06-2025
- RGLS 11-07-2024
- Dividend Yield
- PETS N/A
- RGLS N/A
- EPS Growth
- PETS N/A
- RGLS N/A
- EPS
- PETS N/A
- RGLS N/A
- Revenue
- PETS $259,343,000.00
- RGLS N/A
- Revenue This Year
- PETS N/A
- RGLS N/A
- Revenue Next Year
- PETS $3.36
- RGLS N/A
- P/E Ratio
- PETS N/A
- RGLS N/A
- Revenue Growth
- PETS N/A
- RGLS N/A
- 52 Week Low
- PETS $2.90
- RGLS $1.08
- 52 Week High
- PETS $7.79
- RGLS $3.79
- Technical
- Relative Strength Index (RSI)
- PETS 56.24
- RGLS 54.13
- Support Level
- PETS $5.41
- RGLS $1.52
- Resistance Level
- PETS $6.85
- RGLS $1.70
- Average True Range (ATR)
- PETS 0.45
- RGLS 0.11
- MACD
- PETS -0.01
- RGLS 0.00
- Stochastic Oscillator
- PETS 48.37
- RGLS 44.44
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.